POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium is the major intracellular cation; it maintains intracellular osmolality, cell membrane potential, and normal neuromuscular excitability. Dextrose provides caloric support; sodium chloride maintains extracellular fluid osmolality.
| Metabolism | Potassium is not metabolized; excreted primarily by kidneys. Dextrose is metabolized via glycolysis; sodium chloride is excreted unchanged. |
| Excretion | Renal: >90% excreted unchanged in urine; minimal fecal or biliary elimination. |
| Half-life | Terminal elimination half-life approximately 24 hours; reflects redistribution from intracellular to extracellular compartments; prolonged in renal impairment. |
| Protein binding | Minimal (<2%); not significantly bound to plasma proteins. |
| Volume of Distribution | Approximately 0.5 L/kg (total body water); distributes primarily into intracellular fluid, with only 2% in extracellular space. |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: within minutes (immediate plasma potassium elevation); clinical effect on cardiac conduction within seconds. |
| Duration of Action | Intravenous: short duration (minutes to hours) due to rapid cellular uptake; continuous infusion required for sustained effect. |
| Molecular Weight | 74.55 |
40 mEq potassium chloride intravenously, infused at a rate not exceeding 10 mEq/hour, typically once daily or as needed to correct hypokalemia.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment (GFR <30 mL/min) due to risk of hyperkalemia. In mild to moderate impairment (GFR 30-89 mL/min), use with caution, monitor serum potassium closely, and reduce dose or extend dosing interval as needed. |
| Liver impairment | No specific dose adjustment recommended for hepatic impairment. Monitor serum potassium levels, as patients with cirrhosis may have altered potassium homeostasis. |
| Pediatric use | Dose based on body weight: 0.5-1 mEq/kg/dose IV, infused at a rate not exceeding 0.5 mEq/kg/hour, with a maximum of 40 mEq/day. Administer as part of maintenance or replacement therapy. |
| Geriatric use | Elderly patients may have reduced renal function; start at lower end of dosing range (e.g., 20 mEq initially), monitor serum potassium and renal function closely, and adjust dose to avoid hyperkalemia. |
| 1st trimester | Potassium chloride is generally considered safe in pregnancy when used for replacement therapy. No increased risk of major malformations has been reported. However, avoid excessive doses as hyperkalemia may cause fetal arrhythmias. |
| 2nd trimester | Safe for therapeutic use. Monitor serum potassium to avoid hypo- or hyperkalemia, which can affect fetal muscle and nerve function. |
| 3rd trimester | Safe if indicated. Hyperkalemia near term may cause neonatal bradycardia or other arrhythmias; maintain normokalemia. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium readily crosses the placenta via active transport and diffusion. Maternal-fetal gradient is maintained; fetal levels are closely regulated. Excessive maternal potassium can lead to fetal hyperkalemia. |
| Breastfeeding | Potassium is a normal constituent of breast milk. Supplementation at therapeutic doses is considered compatible with breastfeeding. However, IV administration may cause transient changes in maternal potassium levels; infant exposure via milk is minimal. |
| Lactation Rating | L1: Compatible |
| Teratogenic Risk | POTASSIUM CHLORIDE: No teratogenic effects reported in animal studies; potassium crosses placenta but fetal levels are regulated. DEXTROSE: No teratogenic risk at therapeutic doses; hyperglycemia from excessive glucose may cause fetal macrosomia or neonatal hypoglycemia. SODIUM CHLORIDE: No teratogenic risk; maternal hypernatremia may cause fetal hypernatremia. Overall, considered low risk throughout pregnancy when used as indicated. |
| Fetal Monitoring | Monitor serum potassium, glucose, and sodium levels. Assess fluid status and urine output. Fetal heart rate monitoring if given during labor due to risk of hyperkalemia-induced arrhythmias. |
| Fertility Effects | No known effects on fertility from any component. Hypokalemia or hyperkalemia may impair fertility, but correction with potassium chloride does not adversely affect reproduction. |
■ FDA Black Box Warning
Concentrated potassium chloride solutions (≥20 mEq/100 mL) are for intravenous infusion ONLY after dilution. Rapid infusion may cause fatal hyperkalemia and cardiac arrest.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaAddison's disease (untreated)Acute dehydrationConcomitant use of potassium-sparing diuretics (unless under close monitoring)Crush syndrome or extensive tissue necrosis
| Precautions | Monitor serum potassium, glucose, and electrolytes frequently, Risk of hyperkalemia, especially in renal impairment, Risk of volume overload in heart failure or renal disease, Extravasation may cause tissue necrosis, Administration via central line recommended for concentrations >10% dextrose or >40 mEq/L potassium |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges, tomatoes, potatoes, spinach, avocados) and potassium-containing salt substitutes to prevent hyperkalemia. |
| Clinical Pearls | Do not administer undiluted; must be infused via central line if concentration >40 mEq/L. Infusion rate not to exceed 10-20 mEq/hour (or 400 mEq/24h) to avoid hyperkalemia. Monitor ECG and serum potassium during infusion, especially in renal impairment. Do not use in patients with severe hemolytic reactions or acute dehydration. |
| Patient Advice | This medication is given intravenously to treat or prevent low potassium levels. · Report any symptoms of high potassium such as muscle weakness, irregular heartbeat, or tingling in hands/feet. · Avoid potassium-containing salt substitutes or supplements while on this treatment unless directed by your doctor. · Inform your doctor about all medications, especially potassium-sparing diuretics, ACE inhibitors, or ARBs. |
Loading safety data…